Eli Lilly and Company and Precision BioSciences Inc. announced a research collaboration and exclusive license agreement to use Precision’s ARCUS genome editing platform to research and develop potential in vivo therapies for a series of genetic disorders.
Pfizer snagged Fast Track designation from the U.S. Food and Drug Administration for the company’s Duchenne muscular dystrophy (DMD) gene therapy treatment, PF-06939926.
A little more than one year after Pfizer terminated the company’s studies of PF-06252616 as a potential treatment for Duchenne muscular dystrophy, Swiss pharma giant Roche is following suit with the terminated development of RG6206.
Vertex Pharmaceuticals will acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million.
Capricor Therapeutics Inc. put on hold a clinical trial of the company’s experimental drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.
Britain’s Summit Therapeutics will stop developing the company’s Duchenne muscular dystrophy drug after ezutromid failed a mid-stage study, wiping out nearly 80 percent of its market value.
Wave Life Sciences officially opened a new state-of-the art manufacturing facility to support advancement of the company’s stereopure nucleic acid platform.
Johnson & Johnson’s Janssen Biotech opted out of its licensing deal with Los Angeles-based Capricor Therapeutics for CAP-1002 (allogeneic cardiosphere-derived cells).
2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.
The ninth batch of presidential candidate Hillary Clinton’s emails released by WikiLeaks has some biopharma gossip that includes Clinton’s team discussing the FDA’s commissioner and it’s so-called “war on pharma.”